About
Derek Jantz is Chief Scientific Officer at Tune Therapeutics, where he works on epigenetic programming and gene-expression control therapies. He previously co-founded Precision BioSciences in 2006 and served as its Chief Scientific Officer, helping develop the ARCUS genome editing platform. Public sources portray him primarily as a scientific and operating leader in gene editing rather than an investor or fund manager.
Areas of interest
biotechgene editinggene therapycell therapyepigenetic programmingcancer immunotherapy